
|Videos|May 9, 2014
First-Line Treatment Options for Patients with mCRC
Author(s)Roberto Bordonaro, MD
Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses first-line treatment options for advanced colorectal cancer (CRC).
Advertisement
Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses first-line treatment options for advanced colorectal cancer (CRC).
Clinical Pearls:
- First-line treatment options for patients with advanced CRC are influenced byRASmutation status
- Patients with wild-typeRASare treated with chemotherapy plus anti-EGFR agents, such as panitumumab or cetuximab
- Data from the PRIME trial, which compared FOLFOX plus panitumumab to panitumumab alone, showed that patients treated with panitumumab plus FOLFOX had an improvement in overall survival
- The retrospective study of the CRYSTAL study and data from the FIRE study show that cetuximab prolongs overall survival longer than 30 months in patients who haveRASwild-type disease.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
4
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
5



















